2American Thoracic Society.Centers for Disease Control and Prevention/Infectious Diseases Society of America:Treatment of Tuberculosis[J].Am J Respir Crit CareMed,2003,167:661.
6Daphne Yee.Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis[J].Am J Respir Crit Care Med,2003,(167):1476.
7C.Maldonado Galdeano.Proposed Model:Mechanisms of Immunomodulation Induced by Probiotic Bacteria[J].Clin.Vaccine Immuno,2007,(14),485.
5Fox W.The current status of short course chemotherapy[J].Bull lnt Union Tuberc,1978,53:268-270
6Piersimoni C,M obiducci V,Bornigca S,et al.In vitro activity of the new quinolone Lomefloxacin against Mycobacteria tuberculosis[J].Am Rev Respir D is,1992,146:1445-1447
7Sulochana S,Rahman F,Paramasivan CN.In vitro activity of fluoroquinolones against Mycobacterium tuberculosis[J].J Chemother.2005,17(2):169-73
8Richeldi L,Covi M,Ferrara G,et al.Clinical use of Lovefloxacin in the long-term treatment of drug resistant tuberculosis[J].Monaldi Arch Chest Dis.2002,57(1):39-43
9Yee D,Valiquette C,Pelletier M,et al.Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis[J].Am J Respir Crit Care Med.2003,167(11):1472-1477
10Jacobs TO, Pamies RJ. Adult costipation a review and clinical guide[J]. J Natl Med Assoc, 2001,93 ( 1 ): 22.
